Brokerage : SK Securities
Analyst : Seon-kyoung Lee
Investment Rating : BUY (Maintained)
Target Price : KRW 260,000 (Maintained)
Core Momentum : Full-fledged profitability improvement driven by expanding sales mix of new product portfolios and increasing fixed-cost leverage supported by scheduled 2H US launches
📊 1. [Valuation & Key Financial Metrics]
- Rating and Target Price: BUY (Maintained), Target Price KRW 260,000 (Maintained), offering 33.5% upside potential against the base share price of KRW 194,700 (as of 26/05/06).
- Consolidated Earnings Forecasts & Upward Revisions:
- 2026F Revised Outlook: Revenue KRW 5,308B (+27.5% YoY, +2.0% vs prior estimate, +0.5% vs consensus), Operating Profit KRW 1,733B (+48.3% YoY, OPM 32.6%, +8.4% vs prior estimate, +0.1% vs consensus), Net Profit (Controlling) KRW 1,431B (+7.7% vs prior estimate, Net Margin 27.0%).
- 1Q26 Earnings Review:
- Consolidated Revenue KRW 1,145.0B (+36% YoY, -13.9% QoQ) and Operating Profit KRW 321.9B (+115.5% YoY, -32.3% QoQ, OPM 28.1%), meeting consensus estimates (Revenue KRW 1,126B, OP KRW 314B).
- Net Profit (Controlling) recorded KRW 262.0B.
🚀 2. [Market Opportunities & Business Outlook]
- 1Q26 Margin Improvement Drivers:
- Despite one-off costs from regular maintenance at the US plant and lower revenue from mature portfolios (Remsima IV, Truxima, Herzuma: KRW 393.0B, -6.5% YoY), robust growth in the new product portfolio (KRW 581.2B, +67.4% YoY) and the easing of post-merger effects drove improvements in both GPM (59.9%, +7.3%p YoY) and OPM (28.1%, +10.4%p YoY).
- New Product Growth and Full-Year Guidance:
- The sales contribution of new products reached 60% in 1Q26, confirming profitability improvements driven by portfolio mix enhancement.
- With Steqeyma’s European indication expansions, scheduled 2H US launches of Omlyclo and Eydenzelt, and steady revenue growth from Zymfentra, the company is well positioned to achieve its annual revenue guidance of KRW 5.3T.
- Operating Leverage Dynamics: As the commercial growth of new products accelerates, increasing fixed-cost leverage is expected to translate top-line expansion into continued profitability gains.
📝 Editor’s Comment (Perspective)
The analyst views Celltrion as entering a phase of improving profitability, supported by rapid growth in new product sales and increasing fixed-cost leverage as revenue expands. This perspective highlights the trajectory of improving operating margins and the growth momentum from scheduled 2H global product launches over transient one-off items like regular US plant maintenance.
To determine whether this investment thesis continues to materialize, key tracking points will be whether the 2H US rollouts of Omlyclo and Eydenzelt, alongside Steqeyma’s European expansion, sustain the sales contribution of new products, and whether steady Zymfentra adoption supports the achievement of full-year revenue guidance (KRW 5.3T) and projected ~32.6% operating margins. These developments can be verified through upcoming quarterly earnings releases, official IR presentations, and periodic corporate filings.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
